Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial

Kerin Adelson, Bhuvaneswari Ramaswamy, Joseph A. Sparano, Paul J. Christos, John J. Wright, George Raptis, Gang Han, Miguel Villalona-Calero, Cynthia X. Ma, Dawn Hershman, Joseph Baar, Paula Klein, Tessa Cigler, G. Thomas Budd, Yelena Novik, Antoinette R. Tan, Susan Tannenbaum, Anupama Goel, Ellis Levine, Charles L. ShapiroEleni Andreopoulou, Michael Naughton, Kevin Kalinsky, Sam Waxman, Doris Germain

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial'. Together they form a unique fingerprint.

Medicine & Life Sciences